drugset / Trial / NCT07864181

TheraCal PT vs. Formocresol in Primary Molar Pulpotomies

NCT07864181 ↗

Phase 1/2 Completed 50 enrolled Hama University
RandomizedParallel-groupSingle-blindTreatment

Summary

This prospective, randomized, parallel-group clinical trial evaluated the 12-month clinical and radiographic success rates of TheraCal PT versus formocresol in primary molar vital pulpotomies among 50 children aged 5 to 8 years. At the conclusion of the follow-up period, both materials demonstrated a 100% clinical success rate, while radiographic success rates were 92% for the formocresol group and 80% for the TheraCal PT group, showing no statistically significant differences between the two treatments.

Timeline

Start
2024-01-01
Primary completion
2025-06-03
Completion
2025-12-23

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject TheraCal PT Other / unclassified — —

Indications